Ashwani Verma
Stock Analyst at UBS
(3.69)
# 757
Out of 5,152 analysts
104
Total ratings
48.65%
Success rate
8.86%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Buy | $248 → $251 | $162.96 | +54.03% | 7 | Feb 24, 2026 | |
| HRMY Harmony Biosciences Holdings | Downgrades: Neutral | $43 → $46 | $28.24 | +62.89% | 4 | Feb 11, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $178 | $130.76 | +36.13% | 11 | Jan 23, 2026 | |
| INSM Insmed | Maintains: Buy | $223 → $215 | $144.23 | +49.07% | 1 | Jan 6, 2026 | |
| UTHR United Therapeutics | Maintains: Buy | $600 → $645 | $482.93 | +33.56% | 11 | Jan 6, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $40 | $22.90 | +74.67% | 9 | Jan 6, 2026 | |
| CORT Corcept Therapeutics | Initiates: Neutral | $95 | $35.01 | +171.39% | 1 | Dec 16, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $54 → $48 | $17.62 | +172.42% | 4 | Dec 8, 2025 | |
| BHVN Biohaven | Downgrades: Neutral | $26 → $11 | $10.46 | +5.16% | 5 | Nov 26, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $163 → $188 | $188.23 | -0.12% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $3.99 | +150.63% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $195 → $220 | $230.82 | -4.69% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $40 | $40.61 | -1.50% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $31.80 | -18.24% | 10 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $68 | $99.04 | -31.34% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $26.89 | -33.06% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $28.29 | +48.46% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $61.12 | -32.92% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.80 | -41.67% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $114.31 | -0.27% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $46.48 | -39.76% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $269.61 | -97.40% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $14.69 | -18.31% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.35 | +1,015.24% | 1 | Oct 11, 2022 |
Axsome Therapeutics
Feb 24, 2026
Maintains: Buy
Price Target: $248 → $251
Current: $162.96
Upside: +54.03%
Harmony Biosciences Holdings
Feb 11, 2026
Downgrades: Neutral
Price Target: $43 → $46
Current: $28.24
Upside: +62.89%
Neurocrine Biosciences
Jan 23, 2026
Maintains: Buy
Price Target: $188 → $178
Current: $130.76
Upside: +36.13%
Insmed
Jan 6, 2026
Maintains: Buy
Price Target: $223 → $215
Current: $144.23
Upside: +49.07%
United Therapeutics
Jan 6, 2026
Maintains: Buy
Price Target: $600 → $645
Current: $482.93
Upside: +33.56%
ACADIA Pharmaceuticals
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $22.90
Upside: +74.67%
Corcept Therapeutics
Dec 16, 2025
Initiates: Neutral
Price Target: $95
Current: $35.01
Upside: +171.39%
Legend Biotech
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $17.62
Upside: +172.42%
Biohaven
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $10.46
Upside: +5.16%
Jazz Pharmaceuticals
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $188.23
Upside: -0.12%
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $3.99
Upside: +150.63%
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $230.82
Upside: -4.69%
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $40.61
Upside: -1.50%
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $31.80
Upside: -18.24%
Jul 30, 2025
Maintains: Neutral
Price Target: $62 → $68
Current: $99.04
Upside: -31.34%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $26.89
Upside: -33.06%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $28.29
Upside: +48.46%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $61.12
Upside: -32.92%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.80
Upside: -41.67%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $114.31
Upside: -0.27%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $46.48
Upside: -39.76%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $269.61
Upside: -97.40%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $14.69
Upside: -18.31%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.35
Upside: +1,015.24%